IL299051A - Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Info

Publication number
IL299051A
IL299051A IL299051A IL29905122A IL299051A IL 299051 A IL299051 A IL 299051A IL 299051 A IL299051 A IL 299051A IL 29905122 A IL29905122 A IL 29905122A IL 299051 A IL299051 A IL 299051A
Authority
IL
Israel
Prior art keywords
seq
cancer
peptide
cell
tumor
Prior art date
Application number
IL299051A
Other languages
English (en)
Hebrew (he)
Inventor
Schuster Heiko
Peper Janet
Kevin R?HLE
Wagner Philipp
Rammensee Hans-Georg
Original Assignee
Immatics Biotechnologies Gmbh
Schuster Heiko
Peper Janet
Kevin R?HLE
Wagner Philipp
Hans Georg Rammensee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh, Schuster Heiko, Peper Janet, Kevin R?HLE, Wagner Philipp, Hans Georg Rammensee filed Critical Immatics Biotechnologies Gmbh
Priority claimed from PCT/EP2018/051952 external-priority patent/WO2018138257A1/en
Publication of IL299051A publication Critical patent/IL299051A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001136Cytokines
    • A61K39/001138Tumor necrosis factors [TNF] or CD70
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001148Regulators of development
    • A61K39/001149Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001162Kinases, e.g. Raf or Src
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001163Phosphatases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/00117Mucins, e.g. MUC-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/892Reproductive system [uterus, ovaries, cervix, testes]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
IL299051A 2017-01-27 2018-01-26 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers IL299051A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451255P 2017-01-27 2017-01-27
DE102017101671 2017-01-27
PCT/EP2018/051952 WO2018138257A1 (en) 2017-01-27 2018-01-26 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Publications (1)

Publication Number Publication Date
IL299051A true IL299051A (en) 2023-02-01

Family

ID=61148200

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299051A IL299051A (en) 2017-01-27 2018-01-26 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL268278A IL268278B2 (en) 2017-01-27 2019-07-25 New peptides and their combinations for immunotherapy against ovarian cancer and other cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL268278A IL268278B2 (en) 2017-01-27 2019-07-25 New peptides and their combinations for immunotherapy against ovarian cancer and other cancers

Country Status (23)

Country Link
US (10) US11248035B1 (enExample)
EP (2) EP4035675A3 (enExample)
JP (2) JP7337695B2 (enExample)
KR (2) KR102699622B1 (enExample)
CN (1) CN110198734A (enExample)
AU (6) AU2018212584B2 (enExample)
BR (1) BR112019015237A2 (enExample)
CA (1) CA3048108A1 (enExample)
CL (8) CL2019002093A1 (enExample)
CO (1) CO2019008008A2 (enExample)
CR (4) CR20210128A (enExample)
ES (1) ES2946584T3 (enExample)
HR (1) HRP20230512T8 (enExample)
IL (2) IL299051A (enExample)
LT (1) LT3573647T (enExample)
MX (1) MX2019008843A (enExample)
NZ (1) NZ754139A (enExample)
PE (1) PE20191248A1 (enExample)
PH (1) PH12019501377A1 (enExample)
RS (1) RS64217B1 (enExample)
SG (2) SG10202108122YA (enExample)
SI (1) SI3573647T1 (enExample)
TW (1) TW202325724A (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
EA201991444A1 (ru) * 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
CA3150963C (en) 2019-08-28 2023-01-03 Dairycs Automatic Milking Ltd A dairy farm with a single or multiple frontal elevated roads
BR112022009087A2 (pt) * 2019-11-11 2022-07-26 Ibi Ag Innovative Bio Insecticides Ltd Nanocorpos para controle de insetos e usos dos mesmos
CN110838372B (zh) * 2019-11-18 2022-07-12 武汉大学 一种个性化癌症用药数据库系统及建立方法
CN111363744B (zh) * 2020-02-26 2021-08-24 暨南大学 小檗碱介导的uhrf1基因抑制及其在制备治疗多发性骨髓瘤药物中的用途
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN114107502A (zh) * 2021-11-29 2022-03-01 四川大学华西医院 一种上尿路上皮癌诊断标志物及其应用
CN115948557B (zh) * 2023-01-04 2025-09-02 陕西师范大学 一种nlrp2作为靶点在卵巢癌疾病诊断和/或治疗中的应用
CN116350787B (zh) * 2023-03-15 2025-04-01 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) Rbm15的抑制剂在卵巢癌紫杉醇化疗耐药中的应用
CN117210561A (zh) * 2023-05-09 2023-12-12 山东第一医科大学第一附属医院(山东省千佛山医院) Rnf106在食管鳞癌检测、治疗和预后靶点及应用
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用
CN117233393B (zh) * 2023-11-15 2024-02-09 四川大学华西医院 双重免疫组化染色试剂盒及其在鉴别良恶性胆管上皮肿瘤中的应用
CN118166098B (zh) * 2024-02-05 2024-09-10 北京大学深圳医院 检测magea4-as1的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009638A1 (en) * 1996-09-06 1998-03-12 The Brigham And Women's Hospital, Inc. INHIBITION OF MAST CELL ACTIVATION BY gp49-BASED MECHANISMS AND REAGENTS
US6514935B1 (en) * 1997-03-14 2003-02-04 President And Fellows Of Harvard Methods of treating hypertension
GB0017512D0 (en) * 2000-07-17 2000-08-30 Smithkline Beecham Biolog Novel compounds
JP2005511012A (ja) * 2001-08-10 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトcDNAおよびタンパク質およびその使用
AU2002324700A1 (en) * 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CN1691964A (zh) * 2002-09-06 2005-11-02 曼康公司 表位序列
WO2005017102A2 (en) * 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
CA2546794C (en) * 2003-11-19 2013-09-17 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
KR20080003321A (ko) * 2005-02-24 2008-01-07 세미네스 인코퍼레이티드 생물학적 샘플을 분류하는 조성물 및 방법
PL1760088T3 (pl) 2005-09-05 2008-10-31 Immatics Biotechnologies Gmbh Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
CN106220721B (zh) * 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
CN105566450A (zh) 2007-07-27 2016-05-11 伊玛提克斯生物技术有限公司 免疫疗法的新型免疫抗原表位
HUE037973T2 (hu) * 2008-04-17 2018-09-28 Io Biotech Aps Indolamin-2,3-dioxigenáz-alapú immunterápia
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US8710014B2 (en) 2010-10-08 2014-04-29 Proteapex Therapeutics Llc Compositions and methods for inhibition of MMP13:MMP-substrate interactions
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Also Published As

Publication number Publication date
AU2018212584B2 (en) 2020-12-10
EP3573647B1 (en) 2023-04-05
CL2021002460A1 (es) 2022-06-24
KR20240134224A (ko) 2024-09-06
US20230365651A1 (en) 2023-11-16
CN110198734A (zh) 2019-09-03
US20230312680A1 (en) 2023-10-05
US20210340216A1 (en) 2021-11-04
SG11201906198PA (en) 2019-08-27
JP2020506690A (ja) 2020-03-05
US12065477B2 (en) 2024-08-20
KR102699622B1 (ko) 2024-08-28
CL2021002459A1 (es) 2022-06-24
IL268278B1 (en) 2023-01-01
AU2018212584A1 (en) 2019-06-20
EP3573647A1 (en) 2019-12-04
HRP20230512T8 (hr) 2023-09-15
CL2020000817A1 (es) 2020-10-16
US11345737B1 (en) 2022-05-31
AU2021201348A1 (en) 2021-03-18
US11919940B2 (en) 2024-03-05
MX2019008843A (es) 2019-12-09
CR20190388A (es) 2019-10-16
TW202325724A (zh) 2023-07-01
SI3573647T1 (sl) 2023-07-31
US20220356227A1 (en) 2022-11-10
AU2021201350A1 (en) 2021-03-18
SG10202108122YA (en) 2021-09-29
JP7337695B2 (ja) 2023-09-04
US20240034769A1 (en) 2024-02-01
AU2021201349A1 (en) 2021-03-18
CL2022003407A1 (es) 2023-05-26
IL268278A (en) 2019-09-26
PH12019501377A1 (en) 2020-02-10
US20240076349A1 (en) 2024-03-07
ES2946584T3 (es) 2023-07-21
CO2019008008A2 (es) 2019-10-21
CR20210128A (es) 2021-04-26
AU2021201350B2 (en) 2024-02-01
KR20190112271A (ko) 2019-10-04
US20230002473A1 (en) 2023-01-05
PE20191248A1 (es) 2019-09-18
EP4035675A2 (en) 2022-08-03
IL268278B2 (en) 2023-05-01
HRP20230512T1 (hr) 2023-08-04
US11214608B2 (en) 2022-01-04
LT3573647T (lt) 2023-06-12
BR112019015237A2 (pt) 2020-04-14
CA3048108A1 (en) 2018-08-02
AU2021201350B9 (en) 2024-02-22
US11858978B2 (en) 2024-01-02
EP4035675A3 (en) 2022-11-16
CL2021002461A1 (es) 2022-06-24
US11248035B1 (en) 2022-02-15
RS64217B1 (sr) 2023-06-30
CL2022003406A1 (es) 2023-05-26
US20230002474A1 (en) 2023-01-05
AU2021201347A1 (en) 2021-03-18
CR20210130A (es) 2021-03-31
AU2021201346A1 (en) 2021-03-18
CL2022002923A1 (es) 2023-04-14
CL2019002093A1 (es) 2019-11-29
JP2023179415A (ja) 2023-12-19
NZ754139A (en) 2022-07-01
CR20210129A (es) 2021-03-26

Similar Documents

Publication Publication Date Title
IL299051A (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
de Oliveira et al. Long non‐coding RNAs in cancer: another layer of complexity
Swarts et al. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities
Huang et al. SNHG8 is identified as a key regulator of epstein-barr virus (EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression
Huang et al. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis
US11840562B2 (en) Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Planells-Palop et al. Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis
WO2018138257A1 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Kulaeva et al. mRNA-lncRNA gene expression signature in HPV-associated neoplasia and cervical cancer
Xu et al. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer
Hasan An overview of promising biomarkers in cancer screening and detection
Zhang et al. LINC01232 promotes lung squamous cell carcinoma progression through modulating miR-181a-5p/SMAD2 axis
Xie et al. nMET, a new target in recurrent Cancer
CN118317783A (zh) 肽疫苗
Cho et al. Human Puf-A, a novel component of 90S pre-ribosome, links ribosome biogenesis to cancer progression
Chen et al. Mechanism of competitive binding of miR-106b-5p by circRNA-ITCH to target and regulate SETD2 to inhibit prostate cancer progression
Brune et al. Appendix A: Loss of IRF5 increases ribosome biogenesis leading to alterations in mammary gland architecture and metastasis
Ma et al. H3K27ac-induced lncRNA PAXIP1-AS1 exhibits oncogenic property in ovarian cancer by targeting miR-6744-5p/PCBP2 axis
Chiadini Study of the interactions between CD99, immunologic microenvironment and microRNAs and their prognostic significance in human osteosarcoma
Gonçalves Deciphering key roles of WNT6 in glioblastoma: mechanistic, functional, and clinical insights
Kolla et al. in Human Cancers: 10 Years Later CHD5 Role of
Rogers Cancer gene discovery and immunosurveillance studies using Sleeping Beauty mouse models